sameAs
Alopecia areata in patients with inflammatory bowel disease: an overviewClinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndromeElevated risk of venous thromboembolic events in patients with inflammatory myopathiesRole of environmental pollution in irritable bowel syndromeThe role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspectiveNon-specific abdominal pain and air pollution: a novel associationPolyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal CancerInhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tractBerberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent MannerNeuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in miceCharacterization and distribution of NKD, a receptor for Drosophila tachykinin-related peptide 6.Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patientsReview article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.Young Talent Group launches actions for young gastroenterologists by introducing the UEG Young GI Network.Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review.Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors.Opioid receptors and their ligands.Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment.Structure-activity relationship, conformation and pharmacology studies of morphiceptin analogues--selective mu-opioid receptor ligands.Synthesis of target-specific radiolabeled peptides for diagnostic imaging.Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors.Distribution, function and physiological role of melatonin in the lower gut.Prevention and therapeutic strategies of thromboembolic events in patients with inflammatory bowel diseases: a report of three cases.Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease.Experimental colitis in mice is attenuated by topical administration of chlorogenic acid.Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.Opioid peptides in cancer.RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectivesNociceptin effect on intestinal motility depends on opioid-receptor like-1 receptors and nitric oxide synthase co-localization.Kinetic studies of novel inhibitors of endomorphin degrading enzymesThe influence of family pattern abnormalities in the early stages of life on the course of inflammatory bowel diseases.Brain-Gut Interactions in IBSMean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study.The endomorphin system and its evolving neurophysiological role.Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice.Endomorphin analogs.Enzymatic degradation of endomorphins.Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in miceEndocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.
P50
Q26741868-1E649CCC-E266-4A6C-8A2A-AD2F2428E6A4Q26743440-C2352AF1-DCC9-4975-890A-6AA0954C7AB5Q26746904-41DB49A2-0A4E-4358-8CD5-56675B781BB1Q26777544-6717F26D-DF00-4977-B146-369CBAFA0AD9Q26795563-2E01A2F1-5F3F-4C21-AB53-BBDCDB6CE5B1Q27313667-1BE63EB0-F738-47B4-B7E3-24F5E53F225BQ28071957-25B0C32A-0E85-46AB-A759-52AB2C79967FQ28302731-30414C37-5EFC-4E2E-815B-0FDBB7D5CEEAQ28551749-D307AF98-FA8C-4A3D-8354-8969D33AA027Q28834404-767B4871-8F97-4197-943D-82536BF398B0Q33385886-62A0CC43-8866-49B0-AA89-B5223FEAA391Q33735385-64820EEA-4858-4559-865D-A9D6D4D81BB5Q33785337-DCE8EB29-3601-4A66-AF83-5BFF4C684CC3Q33965155-D012F557-B216-4762-80E1-EEC08BA73A07Q34100569-A3ECF071-3FE5-4BCF-A3C7-78C02B00CB4BQ34219916-A2EB1DBB-1F8A-41CE-943F-36C2C199412CQ34293862-A49AC670-F74D-4A18-9B89-3E8961810A49Q34534223-1EBCA120-0EC5-4022-A7BB-C4368A74B5EEQ34948349-9F12F9E2-F2D5-4373-861B-4A74C2B6C80DQ35044474-36390564-BC37-4499-B6CF-886D936EEC1DQ35294138-DF13C4FF-77A0-4ED7-AD11-55E28ACC0446Q35404204-2F2D9C5A-4830-46BA-B9CF-96DC4872E074Q35405694-4EED6976-20A8-4E69-8A97-D5FABCF0D85EQ35589795-D83D7CB0-254A-431D-801A-0FFFED624171Q35626127-90E91651-A5F7-4A92-B6F0-77672B46614BQ35783889-D6422BC5-E790-424E-A5FD-88E1C2FEFF08Q35805281-18F31147-79BB-419A-AD09-7E32F3D1CA3BQ35906057-4F9915D9-845D-44FC-ACFF-A9FCDEB03540Q35922020-50D496D5-6C30-4FA9-A824-251CE497D662Q35985375-C00EAB7F-C3BA-4D2E-9837-FE7BCE4C192CQ36023239-275ABAB8-022B-43FA-951A-9D195176BCD4Q36076024-71A3EFED-5ACA-4AB0-9E28-B0C3AE7F237EQ36510978-EAF9C93E-F2EC-4B5E-B68C-0DD261C491E1Q36747911-D48A806B-71CB-4839-822D-6EF7B948BC5DQ36772909-5BCB5EE0-0AD0-4EFC-A948-F3EA25C546BAQ37066110-72138D6F-E26E-48C5-B76F-3A6CD32F82EFQ37249024-84C6F244-595B-46A0-B1FF-19748DE26FB9Q37340687-06B8BE4A-D5C7-40FE-A197-755E321574C0Q37416662-F0E3C837-F8B5-4684-9BC9-521BBDB83641Q37491434-2F2B6CF2-9568-455A-B3D9-296246250260
P50
description
Polish biochemist and gastroenterologist
@en
bioquímicu polacu
@ast
polnischer Biochemiker
@de
polski biochemik i gastroenterolog
@pl
name
Jakub Fichna
@ast
Jakub Fichna
@ca
Jakub Fichna
@de
Jakub Fichna
@en
Jakub Fichna
@es
Jakub Fichna
@fr
Jakub Fichna
@ga
Jakub Fichna
@it
Jakub Fichna
@nl
Jakub Fichna
@pl
type
label
Jakub Fichna
@ast
Jakub Fichna
@ca
Jakub Fichna
@de
Jakub Fichna
@en
Jakub Fichna
@es
Jakub Fichna
@fr
Jakub Fichna
@ga
Jakub Fichna
@it
Jakub Fichna
@nl
Jakub Fichna
@pl
altLabel
Jakub Jerzy Fichna
@pl
prefLabel
Jakub Fichna
@ast
Jakub Fichna
@ca
Jakub Fichna
@de
Jakub Fichna
@en
Jakub Fichna
@es
Jakub Fichna
@fr
Jakub Fichna
@ga
Jakub Fichna
@it
Jakub Fichna
@nl
Jakub Fichna
@pl
P1053
S-6641-2016
P1412
P1559
Jakub Fichna
@pl
P21
P214
310144782731106965262
P27
P31
P3124
P3829
P496
0000-0002-8443-4417
P7859
lccn-n2017186129